An HCPLive year-end article about 2025 coverage of C3 glomerulopathy, or C3G, included perspective from Jared R. Hassler, MD, Associate Professor of Pathology and Laboratory Medicine at the Lewis Katz School of Medicine at Temple University, on the significance and impact of the U.S. Food and Drug Administration’s approval of Novartis’ oral iptacopan (Fabhalta), which marked the first FDA-approved drug for patients with the ultra-rare kidney disease.
IMPORTANT: Labor & Delivery services have moved from Temple University Hospital–Main Campus (Broad & Ontario) to our new women & families hospital.
800-TEMPLE-MED
Schedule Appointment
SEARCH TEMPLE HEALTH